Works matching DE "CANAGLIFLOZIN"
Results: 680
Expanding access to sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the Ministry of Health Malaysia – a multiple HTA approach.
- Published in:
- International Journal of Technology Assessment in Health Care, 2024, v. 40, n. 1, p. 1, doi. 10.1017/S0266462324000643
- Publication type:
- Article
Canagliflozin Alleviates Atherosclerosis Progression through Inflammation, Oxidative Stress, and Autophagy in Western Diet-fed ApoE<sup>−/−</sup> Mice.
- Published in:
- Cardiovascular Innovations & Applications (CVIA), 2024, v. 9, p. 1, doi. 10.15212/CVIA.2023.0093
- By:
- Publication type:
- Article
Effect of Peroral Administration of Chromium on Insulin Signaling Pathway in Skeletal Muscle Tissue of Holstein Calves.
- Published in:
- Biological Trace Element Research, 2017, v. 180, n. 2, p. 223, doi. 10.1007/s12011-017-1007-1
- By:
- Publication type:
- Article
Novel LC–MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study.
- Published in:
- BMC Chemistry, 2019, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13065-019-0597-4
- By:
- Publication type:
- Article
URINARY TRACT INFECTION (UTI) IN POSTMENOPAUSAL WOMEN WITH TYPE 2 DIABETES MELLITUS USING SODIUM-GLUCOSE CO TRANSPORTER 2 INHIBITORS (SGLT-2 I).
- Published in:
- Journal of Medical Sciences (1997-3438), 2024, v. 32, n. 2, p. 143, doi. 10.52764/jms.24.32.2.5
- By:
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences in adults.
- Published in:
- Diabetes & Primary Care, 2023, v. 25, n. 1, p. 9
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences (England, Scotland and Wales).
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 6, p. 175
- Publication type:
- Article
CREDENCE trial stopped early.
- Published in:
- Diabetes & Primary Care, 2018, v. 20, n. 3, p. 104
- By:
- Publication type:
- Article
OBSERVE-4D.
- Published in:
- Diabetes & Primary Care, 2018, v. 20, n. 3, p. 102
- By:
- Publication type:
- Article
Pharmacological effect of sodium-glucose cotransporter 2 inhibitors in reducing the incidence of nephrolithiasis.
- Published in:
- Journal of Parathyroid Disease, 2023, v. 11, n. 1, p. 1, doi. 10.34172/jpd.2023.11220
- By:
- Publication type:
- Article
Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis.
- Published in:
- Open Veterinary Journal, 2022, v. 12, n. 4, p. 511, doi. 10.5455/OVJ.2022.v12.i4.14
- By:
- Publication type:
- Article
Heterogenous expression of endocrine and progenitor cells within the neonatal porcine pancreatic lobes–Implications for neonatal porcine islet xenotransplantation.
- Published in:
- Xenotransplantation, 2023, v. 30, n. 2, p. 1, doi. 10.1111/xen.12793
- By:
- Publication type:
- Article
Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383
- By:
- Publication type:
- Article
Canagliflozin or acarbose versus placebo to ameliorate post‐bariatric hypoglycaemia – The HypoBar I randomized clinical trial protocol.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 6, p. 1, doi. 10.1111/dme.15320
- By:
- Publication type:
- Article
The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 5, p. 1, doi. 10.1111/dme.15271
- By:
- Publication type:
- Article
Poster abstracts.
- Published in:
- Diabetic Medicine, 2024, v. 41, p. 1, doi. 10.1111/dme.15296
- Publication type:
- Article
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14769
- By:
- Publication type:
- Article
Basic and clinical science posters: Vascular and endothelial function.
- Published in:
- Diabetic Medicine, 2021, v. 38, p. 1, doi. 10.1111/dme.22_14556
- Publication type:
- Article
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262
- By:
- Publication type:
- Article
SGLT2 inhibitors in Type 1 diabetes: is this the future?
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 12, p. 1642, doi. 10.1111/dme.13791
- By:
- Publication type:
- Article
Unmasking and aggravation of polycythemia vera by canagliflozin.
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 11, p. 1613, doi. 10.1111/dme.13706
- By:
- Publication type:
- Article
Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
- Published in:
- Diabetic Medicine, 2016, v. 33, n. 12, p. 1744, doi. 10.1111/dme.13033
- By:
- Publication type:
- Article
Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1366439
- By:
- Publication type:
- Article
Emerging role of antidiabetic drugs in cardiorenal protection.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1349069
- By:
- Publication type:
- Article
Modeling the protein binding nonlinearity in population pharmacokinetic model of valproic acid in children with epilepsy: a systematic evaluation study.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1228641
- By:
- Publication type:
- Article
Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1α inhibition.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1152611
- By:
- Publication type:
- Article
Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports.
- Published in:
- Journal of Anesthesia, 2023, v. 37, n. 3, p. 465, doi. 10.1007/s00540-023-03174-8
- By:
- Publication type:
- Article
The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
- Published in:
- Drugs, 2019, v. 79, n. 7, p. 733, doi. 10.1007/s40265-019-01086-0
- By:
- Publication type:
- Article
Canagliflozin: A Review in Type 2 Diabetes.
- Published in:
- Drugs, 2017, v. 77, n. 14, p. 1577, doi. 10.1007/s40265-017-0801-6
- By:
- Publication type:
- Article
Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.1011669
- By:
- Publication type:
- Article
Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A metaanalysis of randomized controlled trials.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.935039
- By:
- Publication type:
- Article
Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.802992
- By:
- Publication type:
- Article
Euglycemic Ketoacidosis in a Patient without Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 1, p. 109, doi. 10.1007/s13300-022-01339-4
- By:
- Publication type:
- Article
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 5, doi. 10.1007/s13300-022-01277-1
- By:
- Publication type:
- Article
Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 8, p. 2165, doi. 10.1007/s13300-021-01101-2
- By:
- Publication type:
- Article
Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 2, p. 499, doi. 10.1007/s13300-020-00953-4
- By:
- Publication type:
- Article
Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 1, p. 453, doi. 10.1007/s13300-020-00971-2
- By:
- Publication type:
- Article
Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 1, p. 313, doi. 10.1007/s13300-020-00968-x
- By:
- Publication type:
- Article
Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 12, p. 2845, doi. 10.1007/s13300-020-00928-5
- By:
- Publication type:
- Article
Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 10, p. 2371, doi. 10.1007/s13300-020-00914-x
- By:
- Publication type:
- Article
Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 6, p. 1237, doi. 10.1007/s13300-020-00826-w
- By:
- Publication type:
- Article
Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 347, doi. 10.1007/s13300-019-00717-9
- By:
- Publication type:
- Article
Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 6, p. 2219, doi. 10.1007/s13300-019-00708-w
- By:
- Publication type:
- Article
Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 6, p. 2045, doi. 10.1007/s13300-019-00689-w
- By:
- Publication type:
- Article
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1771, doi. 10.1007/s13300-019-00686-z
- By:
- Publication type:
- Article
Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1835, doi. 10.1007/s13300-019-0666-7
- By:
- Publication type:
- Article
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1595, doi. 10.1007/s13300-019-0657-8
- By:
- Publication type:
- Article
Adverse Drug Events Associated with sitagliptin Versus canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 1883, doi. 10.1007/s13300-018-0481-6
- By:
- Publication type:
- Article
Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 3, p. 919, doi. 10.1007/s13300-018-0420-6
- By:
- Publication type:
- Article